- Home
- SWX vs ORKA Comparison
SWX vs ORKA Comparison
Compare SWX & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SWX | ORKA |
|---|---|---|
| Founded | 1931 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.6B |
| IPO Year | 2017 | 1997 |
Fundamental Metrics
Financial Performance| Metric | SWX | ORKA |
|---|---|---|
| Price | $82.58 | $79.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $100.50 | ★ $155.00 |
| AVG Volume (30 Days) | 577.4K | ★ 873.8K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 120.29 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $5,433,972,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | $33.46 | ★ N/A |
| Revenue Growth | ★ 9.56 | N/A |
| 52 Week Low | $76.74 | $22.12 |
| 52 Week High | $94.47 | $115.52 |
Technical Indicators
Market Signals| Indicator | SWX | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 31.19 |
| Support Level | $81.21 | $54.31 |
| Resistance Level | $89.58 | $97.45 |
| Average True Range (ATR) | 1.32 | 4.39 |
| MACD | 0.10 | -0.89 |
| Stochastic Oscillator | 32.18 | 6.36 |
Price Performance
Historical ComparisonAbout SWX Southwest Gas Holdings Inc. (DE)
Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.